カート
- すべて
削除
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
1 mg | ¥15,000 | ||
5 mg | ¥29,500 | ||
10 mg | ¥51,000 | ||
25 mg | ¥104,500 | ||
50 mg | ¥154,500 | ||
100 mg | ¥219,500 | ||
500 mg | ¥441,000 |
PI-273, a Substrate-Competitive, Specific Small-Molecule Inhibitor of PI4KII | |
Targets&IC50 | PI4KII |
In vitro | PI-273 exhibited the greatest inhibitory effect on PI4KII |
In vivo | PI-273 (intraperitoneal injection; 25 mg/kg/day; 15 days) significantly reduces tumor volume and weight in MCF-7 xenografts [1]. PI-273 (0.5 mg/kg intravenously or 1.5 mg/kg intragastrically; 0.08-5 hours) has a half-life of 0.411 hours for intravenous administration and 1.321 hours for intragastric administration, with an absolute bioavailability of 5.1% [1]. |
381.9 | |
C16H16ClN3O2S2 | |
CAS | 925069-34-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year | |
DMSO: 1 mg/mL, Sonication is recommended. ![]() |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.